StonvexLoading…
StonvexStonvexStonvexCore line items from PCRX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $726.41M | $700.97M | $674.98M | $666.82M |
Operating Income | $19.19M | $-73.37M | $87.67M | $60.02M |
Net Income | $7.03M | $-99.56M | $41.95M | $15.91M |
EPS (Diluted) | $0.16 | $-2.15 | $0.89 | $0.34 |
Total Assets | $1.26B | $1.55B | $1.57B | $1.68B |
Total Liabilities | $571.81M | $775.17M | $704.26M | $906.19M |
Cash & Equivalents | $158.54M | $276.77M | $153.30M | $104.14M |
Free Cash Flow OCF − CapEx | $136.66M | $178.75M | $139.49M | $115.20M |
Shares Outstanding | 41.12M | 46.24M | 46.48M | 45.93M |